terazosin has been researched along with Bladder Neck Obstruction in 22 studies
Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the urodynamic and clinical effects of terazosin in patients with symptomatic benign prostatic hyperplasia (BPH)." | 9.08 | Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia. ( de La Rosette, JJ; de Wildt, MJ; Debruyne, FM; Rosier, FW; van Iersel, MP; Witjes, WP, 1996) |
| "To examine the clinical usefulness of selective and non-selective alpha 1-adrenoceptor antagonists, we compared a selective (tamsulosin) and non-selective (terazosin) alpha 1-adrenoceptor antagonists in the treatment of Chinese patients with benign prostatic hyperplasia (BPH)." | 9.08 | Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. ( Gu, FL; Guo, YL; Na, YJ, 1998) |
| "The efficacy and safety of terazosin, a selective long-acting alpha-1-adrenergic blocker, were evaluated in 45 normotensive patients with symptomatic benign prostatic hyperplasia ranging from 50 to 76 years old." | 9.06 | A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia. ( Knapp-Maloney, G; Lepor, H; Sunshine, H, 1990) |
| "The objective of this meta-analysis of randomized controlled trials (RCTs) of terazosin versus placebo in men with benign prostatic hyperplasia (BPH) was to evaluate the effect of terazosin on lower urinary tract symptoms." | 7.72 | Effect of terazosin on clinical benign prostatic hyperplasia in older adults. ( Ahmed, A; Mudiyala, R, 2003) |
| "To investigate the effectiveness of terazosin, an alpha1-adrenoceptor blocking agent, on bladder neck obstruction (BNO), by assessing the urodynamic hydraulic energy profile." | 7.70 | The effectiveness of terazosin, an alpha1-blocker, on bladder neck obstruction as assessed by urodynamic hydraulic energy. ( Hattori, T; Sakakibara, R; Tojo, M; Yamanishi, T; Yasuda, K, 2000) |
| "Terazosin treatment, even 2 mg." | 5.31 | Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. ( Furuya, S; Itoh, N; Masumori, N; Ogura, H; Sato, Y; Takahashi, A; Tanaka, Y; Tsukamoto, T, 2002) |
| "We evaluated the urodynamic and clinical effects of terazosin in patients with symptomatic benign prostatic hyperplasia (BPH)." | 5.08 | Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia. ( de La Rosette, JJ; de Wildt, MJ; Debruyne, FM; Rosier, FW; van Iersel, MP; Witjes, WP, 1996) |
| "To examine the clinical usefulness of selective and non-selective alpha 1-adrenoceptor antagonists, we compared a selective (tamsulosin) and non-selective (terazosin) alpha 1-adrenoceptor antagonists in the treatment of Chinese patients with benign prostatic hyperplasia (BPH)." | 5.08 | Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. ( Gu, FL; Guo, YL; Na, YJ, 1998) |
| "The efficacy and safety of terazosin, a selective long-acting alpha-1-adrenergic blocker, were evaluated in 45 normotensive patients with symptomatic benign prostatic hyperplasia ranging from 50 to 76 years old." | 5.06 | A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia. ( Knapp-Maloney, G; Lepor, H; Sunshine, H, 1990) |
| "The objective of this meta-analysis of randomized controlled trials (RCTs) of terazosin versus placebo in men with benign prostatic hyperplasia (BPH) was to evaluate the effect of terazosin on lower urinary tract symptoms." | 3.72 | Effect of terazosin on clinical benign prostatic hyperplasia in older adults. ( Ahmed, A; Mudiyala, R, 2003) |
| "To investigate the effectiveness of terazosin, an alpha1-adrenoceptor blocking agent, on bladder neck obstruction (BNO), by assessing the urodynamic hydraulic energy profile." | 3.70 | The effectiveness of terazosin, an alpha1-blocker, on bladder neck obstruction as assessed by urodynamic hydraulic energy. ( Hattori, T; Sakakibara, R; Tojo, M; Yamanishi, T; Yasuda, K, 2000) |
| "Terazosin was initiated at 1 mg daily and gradually increased to the maintenance dose of 5 mg daily during 2 weeks." | 2.72 | The effect of terazosin on functional bladder outlet obstruction in women: a pilot study. ( Burkhard, FC; Kessler, TM; Studer, UE, 2006) |
| "Terazosin has proved to be safe and results in significant improvement in bladder emptying in our patients with posterior urethral valves." | 1.35 | Role of alpha adrenergic blocker in the management of posterior urethral valves. ( Abraham, MK; Damisetti, KR; Kedari, PM; Narayanan, T; Nasir, AR; Puzhankara, R; Sudarsanan, B; Unnithan, GR, 2009) |
| "Terazosin treatment, even 2 mg." | 1.31 | Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. ( Furuya, S; Itoh, N; Masumori, N; Ogura, H; Sato, Y; Takahashi, A; Tanaka, Y; Tsukamoto, T, 2002) |
| "In patients without bladder outlet obstruction (BOO), improvement in maximum flow and symptom scores with little change in the degree of obstruction was most apparent, whereas a decrease of detrusor pressure at maximum flow was observed mainly in patients with BOO." | 1.30 | Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction. ( de la Rosette, JJ; Debruyne, FM; Neal, DE; Robertson, A; Rosier, PF; Witjes, WP, 1997) |
| "Functional bladder neck obstruction has been definitively diagnosed in the last few years due to detailed synchronous pressure flow, electromyography and video urodynamics." | 1.30 | Management of functional bladder neck obstruction in women: use of alpha-blockers and pediatric resectoscope for bladder neck incision. ( Gogoi, S; Kumar, A; Mandhani, A; Srivastava, A, 1999) |
| " The dosage was gradually increased to 1-2 mg twice daily, depending upon patient tolerance and a minimum acceptable systolic blood pressure of 90 mm Hg." | 1.29 | Efficacy and safety of terazosin to improve voiding in spinal cord injury patients. ( Perkash, I, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (50.00) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 1 (4.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abraham, MK | 1 |
| Nasir, AR | 1 |
| Sudarsanan, B | 1 |
| Puzhankara, R | 1 |
| Kedari, PM | 1 |
| Unnithan, GR | 1 |
| Damisetti, KR | 1 |
| Narayanan, T | 1 |
| Van Batavia, JP | 1 |
| Combs, AJ | 1 |
| Horowitz, M | 1 |
| Glassberg, KI | 1 |
| Mudiyala, R | 1 |
| Ahmed, A | 1 |
| Kyprianou, N | 1 |
| Velasco, C | 1 |
| Guarneri, L | 1 |
| Leonardi, A | 1 |
| Testa, R | 1 |
| Kessler, TM | 1 |
| Studer, UE | 1 |
| Burkhard, FC | 1 |
| Stockamp, K | 1 |
| Chancellor, MB | 1 |
| Erhard, MJ | 1 |
| Rivas, DA | 1 |
| Perkash, I | 1 |
| Witjes, WP | 3 |
| Rosier, FW | 1 |
| de Wildt, MJ | 1 |
| van Iersel, MP | 1 |
| Debruyne, FM | 3 |
| de La Rosette, JJ | 4 |
| Rosier, PF | 2 |
| Caris, CT | 1 |
| Lepor, H | 2 |
| Nieder, A | 1 |
| Feser, J | 1 |
| O'Connell, C | 1 |
| Dixon, C | 1 |
| Robertson, A | 1 |
| Neal, DE | 1 |
| Na, YJ | 1 |
| Guo, YL | 1 |
| Gu, FL | 1 |
| Kumar, A | 1 |
| Mandhani, A | 1 |
| Gogoi, S | 1 |
| Srivastava, A | 1 |
| Yamanishi, T | 1 |
| Yasuda, K | 1 |
| Sakakibara, R | 1 |
| Hattori, T | 1 |
| Tojo, M | 1 |
| Caprino, L | 1 |
| Rossi, C | 1 |
| Kortmann, BB | 1 |
| Sonke, GS | 1 |
| Floratos, DL | 1 |
| Kiemeney, LA | 1 |
| Wijkstra, H | 1 |
| Gu, BJ | 1 |
| Ishizuka, O | 1 |
| Igawa, Y | 1 |
| Nishizawa, O | 1 |
| Andersson, KE | 1 |
| Tanaka, Y | 1 |
| Masumori, N | 1 |
| Itoh, N | 1 |
| Sato, Y | 1 |
| Takahashi, A | 1 |
| Ogura, H | 1 |
| Furuya, S | 1 |
| Tsukamoto, T | 1 |
| Knapp-Maloney, G | 1 |
| Sunshine, H | 1 |
4 reviews available for terazosin and Bladder Neck Obstruction
| Article | Year |
|---|---|
Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Topics: Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostate; Prostatic Hype | 2003 |
[Therapy of benign prostatic hyperplasia with alpha receptor blockers].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Receptors, A | 1995 |
[New in Austria approved specialty drugs and new knowledge regarding currently available specialty drugs. Uroflo].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Animals; Dose-Response Relationship, D | 1995 |
[Drugs for the treatment of benign prostatic hypertrophy].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Androgen Antagonists; D | 2000 |
6 trials available for terazosin and Bladder Neck Obstruction
| Article | Year |
|---|---|
The effect of terazosin on functional bladder outlet obstruction in women: a pilot study.
Topics: Adrenergic alpha-Antagonists; Adult; Female; Humans; Middle Aged; Pilot Projects; Prazosin; Prospect | 2006 |
Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Urin | 1996 |
Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.
Topics: Adrenergic alpha-Antagonists; Aged; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prospect | 1997 |
Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Prosta | 1997 |
Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Dose-Response Relations | 1998 |
A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Drug Administration Schedule; Humans; Male; Midd | 1990 |
12 other studies available for terazosin and Bladder Neck Obstruction
| Article | Year |
|---|---|
Role of alpha adrenergic blocker in the management of posterior urethral valves.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Child, Preschool; Cystoscopy; Dose-Response Rela | 2009 |
Primary bladder neck dysfunction in children and adolescents III: results of long-term alpha-blocker therapy.
Topics: Adolescent; Adrenergic alpha-Antagonists; Child; Child, Preschool; Female; Humans; Male; Prazosin; S | 2010 |
Effect of terazosin on clinical benign prostatic hyperplasia in older adults.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Urin | 2003 |
Effects of intravenous and infravesical administration of suramin, terazosin and BMY 7378 on bladder instability in conscious rats with bladder outlet obstruction.
Topics: Administration, Intravesical; Adrenergic alpha-Antagonists; Animals; Female; Infusions, Intravenous; | 2003 |
Clinical effect of alpha-1 antagonism by terazosin on external and internal urinary sphincter function.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Follow-Up Studies; Humans; Male; Middle Aged; Penil | 1993 |
Efficacy and safety of terazosin to improve voiding in spinal cord injury patients.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Aged; Dose-Response Relationship, Drug; H | 1995 |
Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Laser Therapy; Male; Microwaves; Middle Aged; Prazosin; | 1997 |
Management of functional bladder neck obstruction in women: use of alpha-blockers and pediatric resectoscope for bladder neck incision.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Combined Modality Therapy; Equipment Design; Female; Huma | 1999 |
The effectiveness of terazosin, an alpha1-blocker, on bladder neck obstruction as assessed by urodynamic hydraulic energy.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Pra | 2000 |
alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Middle Aged; Prazosin; Quinazolines; Severity of Illness | 2001 |
Role of supraspinal alpha1-adrenoceptors for voiding in conscious rats with and without bladder outlet obstruction.
Topics: Adrenergic alpha-Antagonists; Animals; Consciousness; Female; Injections, Intraventricular; Prazosin | 2002 |
Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Japan; Male; Middle Aged; Muscle Cont | 2002 |